MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
GLTO Galecto
- 4.700
- +0.040+0.86%
Close Dec 20 16:00 ET
6.19MMarket Cap-0.25P/E (TTM)
4.860High4.660Low16.84KVolume4.700Open4.660Pre Close80.08KTurnover1.39%Turnover RatioLossP/E (Static)1.32MShares23.50052wk High0.30P/B5.70MFloat Cap4.40152wk Low--Dividend TTM1.21MShs Float449.750Historical High--Div YieldTTM4.29%Amplitude4.400Historical Low4.755Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Galecto Stock Forum
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
• Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211
• Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)
• BRM-1420 has the potential for enhanced clinical effectivenes...
NEWS
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto, Inc. announced the enrollment of the first patient in an investigator-initiated Phase 2 trial to evaluate GB1211, a galectin-3 inhibitor, in combination with pembrolizumab for metastatic melanoma and head and neck squamous cell carcinoma. Galecto aims to explore GB1211's potential to enhance the effectiveness of pembrolizumab in various can...
@FiReBiTriXiE @jimmy the trader @MangoXXX @PYUN970IHaveChosen @Ripper @Rivera @Trytosaveabit @VinylEagle @Wind_Storm @8 Seconds
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
AH volume 1.2M and growing
positive trial data 👍
2 MINUTES AGO, 4:05 PM EST
VIA GLOBENEWSWIRE
No comment yet